FDA
-
-
-
-
-
-
-
Niagen Bioscience renames research program, cites 300+ collaborations
-
-
-
-
-
-
-
Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
-
-
-
-
-
-
-
Niagen Bioscience to Present at the 38th Annual ROTH Conference
-
-
-
-
-
-
-
Niagen Bioscience receives US patent for IV nicotinamide riboside
-
-
-
-
-
-
-
Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast
-
-
-
-
-
-
-
Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth
-
-
-
-
-
-
-
Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York
-
325,482 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

